Monkeys develop virus immunity after infection, vaccine: studies

Published May 21, 2020
Studies carried out on rhesus macaque monkeys to see whether they develop protective virus immunity. — AFP/File
Studies carried out on rhesus macaque monkeys to see whether they develop protective virus immunity. — AFP/File

Two studies on monkeys published on Wednesday offer hope that humans can develop protective immunity to the novel coronavirus.

The studies, published in the journal Science, looked at a prototype vaccine and whether infection with SARS-CoV-2 provides immunity against re-exposure.

Both questions are critical as researchers tackle the virus, which has infected nearly five million people around the world and caused more than 325,000 deaths.

The studies were carried out on rhesus macaque monkeys to see whether they develop protective virus immunity from natural infection or from a vaccine.

"The global Covid-19 pandemic has made the development of a vaccine a top biomedical priority, but very little is currently known about protective immunity to the SARS-CoV-2 virus," said senior author Dan Barouch, director of the Centre for Virology and Vaccine Research at Beth Israel Deaconess Medical Centre in Boston.

"In these two studies, we demonstrate in rhesus macaques that prototype vaccines protected against SARS-CoV-2 infection and that SARS-CoV-2 infection protected against re-exposure," Barouch said.

In one study carried out by Barouch and other researchers, nine adult rhesus macaque monkeys were infected with the virus.

The monkeys developed Covid-19 symptoms but created protective antibodies and recovered after a few days.

To test their immunity, they were exposed to SARS-CoV-2 again 35 days later for what is called a "re-challenge", and they showed few to no symptoms.

The authors of the study cautioned that further research will be needed because of the "important differences" between SARS-CoV-2 infection in monkeys and humans.

"Rigorous clinical studies will be required to determine whether SARS-CoV-2 infection effectively protects against SARS-CoV-2 re-exposure in humans," they said.

The second study, involving many of the same researchers and led by Jingyou Yu, involved vaccinating 35 adult macaques with DNA vaccine candidates designed to generate protective antibodies.

They were exposed to the coronavirus six weeks later and had developed levels of antibodies in the blood sufficient to neutralise it, the study found.

The levels of antibodies, it said, were similar to those seen in humans recovering from the virus, providing hope that an effective human vaccine can be developed.

"Further research will need to address the important questions of the durability of protective immunity and the optimal vaccine platforms for a SARS-CoV-2 vaccine for humans," the authors of the study said.

Opinion

Long arm of Big Tech
20 Jan 2021

Long arm of Big Tech

How many people would still be alive if Twitter and Facebook had denied Trump a platform to spread lies about Covid-19 a year ago?
Words, words, words
19 Jan 2021

Words, words, words

There was little in terms of contributions in our own language as we wrestled with the pandemic.

Editorial

Updated 20 Jan 2021

Broadsheet judgement

There are plenty of skeletons in the Broadsheet cupboard and they must be brought out into the open.
20 Jan 2021

Unequal justice

IT seems no one wants to testify against former SSP Malir, Rao Anwar. At least five prosecution witnesses, all ...
20 Jan 2021

Schools reopening

THE disruptive impact of Covid-19 on education will be felt for years to come. For countries like Pakistan, where...
Updated 19 Jan 2021

LNG contracts

It is important for industry to reconnect with the national grid and for gas to be allocated for more efficient uses.
19 Jan 2021

Murdered judges

THE continuous violence in Afghanistan has raised serious questions about the sustainability of the peace process, ...
19 Jan 2021

K2 feat

A TEAM of 10 Nepalese mountaineers made history over the weekend as they scaled the world’s second highest peak K2...